Compare Becton Dickinson and Co (BDX) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Li Auto Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Li Auto Inc trades at $12.44 (market cap $12.25B). The key difference: Becton Dickinson and Co is far larger — about 3.4× Li Auto Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| BDX | LI | |
|---|---|---|
Market Cap | $41.51B | $12.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $31.80 |
52-Week Low | $135.49 | $11.74 |
Enterprise Value | $57.97B | $1.17B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Li Auto (LI) trades at $12.18, down 0.66% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025 and faces headwinds from domestic competition and aggressive discounting. Recent news highlights delivery updates and new model launches, but the stock remains under pressure amid broader EV sector challenges.
The outlook is cautious with a consensus price target of $14.80, suggesting potential upside, but risks include profitability concerns, competitive pressures, and volatile cash flows. Recovery hinges on successful execution of the L series and global expansion, with FY2025-2026 seen as trough years before potential improvement from 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
